Compare PRSU & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRSU | FTRE |
|---|---|---|
| Founded | 1926 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 1994 | 2023 |
| Metric | PRSU | FTRE |
|---|---|---|
| Price | $47.33 | $17.79 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $31.67 | $14.06 |
| AVG Volume (30 Days) | 206.8K | ★ 1.6M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,064,987,000.00 | ★ $2,723,400,000.00 |
| Revenue This Year | $4.85 | N/A |
| Revenue Next Year | $4.94 | $3.09 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.48 | 1.00 |
| 52 Week Low | $32.03 | $7.40 |
| 52 Week High | $56.52 | $21.39 |
| Indicator | PRSU | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 38.11 | 46.68 |
| Support Level | $32.90 | $17.37 |
| Resistance Level | $54.24 | $17.81 |
| Average True Range (ATR) | 1.87 | 1.33 |
| MACD | -0.63 | -0.20 |
| Stochastic Oscillator | 25.62 | 6.04 |
Pursuit Attractions and Hospitality Inc is an attractions and hospitality company that owns and operates a collection of inspiring and unforgettable experiences at iconic destinations across the United States, Canada, Iceland and Costa Rica. Its elevated hospitality offerings include point-of-interest attractions and distinctive lodges, as well as integrated restaurants, retail options, and transportation that allow visitors to discover and connect with breathtaking national parks and renowned travel locations.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.